AstraZeneca’s top medical executive Cristian Massacesi will replace Bristol Myers’ current chief medical officer, Samit ...

Bristol-Myers Squibb Co.’s chief medical officer is stepping down from his role after six years at the company, a surprise ...

Bristol Myers Squibb's chief medical officer, Samit Hirawat, is leaving the drugmaker to pursue new professional opportunities.

For the biopharma industry, 2020 was many things, but for Samit Hirawat, M.D., chief medical officer of Bristol Myers Squibb, three things stand out: collaboration, adaptation and evolution.

Samit Hirawat Yes. So, our TIGIT inhibitor is in Phase 1 study, defining the dose and the safety and the profile of the medicine to see if there are signals of activity that we can start to see.

Bristol Myers Squibb exec Samit Hirawat acquires $99,999 in stock ...

The approval of Biogen Inc.’s Aduhelm clarifies the U.S. Food and Drug Administration’s standard for drugs for neurodegenerative diseases, making it easier to design studies for new therapies ...

Samit Hirawat, the EVP of $BMY, bought 1,823 shares of the company on 02-14-2025 for an estimated $99,973. This trade was reported by Quiver Quantitative using data ...

Samit Hirawat, the Executive Vice President and Chief Medical (TASE: BLWV) Officer for Drug Development at Bristol Myers Squibb Co. (NYSE: BMY), recently acquired shares in the company.According ...